A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is key to understanding intrinsic and extrinsic factors that may affect patient response to cancer treatments. This ASCO and Association of Community Cancer Centers (ACCC) Research Statement presents specific recommendations and strategies for the research community to improve EDI in cancer clinical trials. There are six overarching recommendations: (1) clinical trials are an integral component of high-quality cancer care, and every person with cancer should have the opportunity to participate; (2) trial sponsors and investigators should design and implement trials with a focus on reducing barriers and enhancing EDI, and work with sites to conduct trials in ways that increase participation of under-represented populations; (3) trial sponsors, researchers, and sites should form long-standing partnerships with patients, patient advocacy groups, and community leaders and groups; (4) anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving EDI; (5) research stakeholders should invest in programs and policies that increase EDI in trials and in the research workforce; and (6) research stakeholders should collect and publish aggregate data on racial and ethnic diversity of trial participants when reporting results of trials, programs, and interventions to increase EDI. The recommendations are intended to serve as a guide for the research community to improve participation rates among people from racial and ethnic minority populations historically under-represented in cancer clinical trials. ASCO and ACCC will work at all levels to advance the recommendations in this publication.

No abstract

A total of 254 children were examined 36 months after a single application of sealant. In 128 children, 201 permanent first molars were treated with Delton, and, in 126 children, 205 permanent first molars were treated with Nuva-Seal. Delton was completely retained on 80% of all paired permanent first molars, partially retained on 10%, and completely lost on 10% of the study teeth. Nuva-Seal was completely retained on 60% of all paired permanent molars, partially retained on 21%, and completely lost on 19% of the study teeth. Delton was 69% effective in preventing occlusal caries on permanent first molars three years after a single application. Nuva-Seal was 39% effective in preventing occlusal caries on permanent first molars three years after a single application. Both sealants have been shown to prevent dental caries on permanent first molars of children three years after a single application.

No abstract

No abstract